Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Non Operating Income (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Non Operating Income for 10 consecutive years, with -$35.7 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 159.87% to -$35.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$42.6 million through Dec 2025, down 236.71% year-over-year, with the annual reading at -$42.6 million for FY2025, 236.71% down from the prior year.
  • Non Operating Income for Q4 2025 was -$35.7 million at BeOne Medicines, down from -$19.0 million in the prior quarter.
  • The five-year high for Non Operating Income was $336.7 million in Q3 2023, with the low at -$800.2 million in Q4 2021.
  • Average Non Operating Income over 5 years is -$37.2 million, with a median of $447500.0 recorded in 2021.
  • The sharpest move saw Non Operating Income surged 451.16% in 2021, then tumbled 14850.06% in 2022.
  • Over 5 years, Non Operating Income stood at -$800.2 million in 2021, then soared by 102.43% to $19.4 million in 2022, then dropped by 13.83% to $16.7 million in 2023, then crashed by 182.0% to -$13.7 million in 2024, then crashed by 159.87% to -$35.7 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$35.7 million, -$19.0 million, and $8.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.